Recovery of Current through Mutated TASK3 Potassium Channels Underlying Birk Barel SyndromeEmma L. Veale, Alistair Mathie, Ehab Al‐Moubarak et al.|Molecular Pharmacology|2013Cited by 46
Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2Paul D. Wright, Alistair Mathie, Egle Gaurilcikaite et al.|Biochemical and Biophysical Research Communications|2019Cited by 21
Pharmacological Approaches to Studying Potassium ChannelsAlistair Mathie, Yvonne Walsh, Emma L. Veale et al.|Handbook of experimental pharmacology|2021Cited by 21
Aprepitant is a novel, selective activator of the K2P channel TRAAKDavid McCoull, Paul D. Wright, Emma L. Veale et al.|Biochemical and Biophysical Research Communications|2021Cited by 8
Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092Yvonne Walsh, Alistair Mathie, M.J. Leach et al.|Biochemistry and Biophysics Reports|2021Cited by 4